Risk Factors for Severe Hepatic Injury After Introduction of Highly Active Antiretroviral Therapy
JAIDS Journal of Acquired Immune Deficiency SyndromesPublished 1 August 2001
Marina Núñez, Raquel Martins Lana, Juan L. Mendoza, Luz Martı́n-Carbonero, Vincent Soriano
Citations246
SJR quartileQ1
SJR score1.04
SNIP0.81
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Avoidance of alcohol abuse, especially in study subjects coinfected with HCV, will reduce the risk of hepatic injury after HAART, and older age should be considered.
Abstract
Nearly 10% of study subjects who start HAART experience severe transaminase elevation, irrespective of the treatment. Avoidance of alcohol abuse, especially in study subjects coinfected with HCV, will reduce the risk of hepatic injury after HAART. When possible, prior treatment for chronic HCV infection should be considered.
Keywords
Medicine
JAMAHepatotoxicity Associated With Antiretroviral Therapy in Adults Infected With Human Immunodeficiency Virus and the Role of Hepatitis C or B Virus Infection
957 Citations2000Mark Sulkowski
The data indicate that use of ritonavir may increase risk of severe hepatotoxicity, and does not support withholding protease inhibitor therapy from persons coinfected with hepatitis B or C virus.
AIDSHepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection
396 Citations2000Marieke den Brinker, Ferdinand W.N.M. Wit +9 more
HIV-1-infected patients co- Infected with HBV or HCV were at considerably higher risk of developing LEE when HAART was initiated compared with patients without co-infection, but it is usually not necessary to modify antiretroviral therapy.
AIDSHepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors
258 Citations1998Mina John, James Flexman +1 more
Hepatitis in HCV–HIV-coinfected patients following treatment with potent antiretroviral therapy may reflect restoration of anti-HCV immune responses rather than increased HCV replication or a hepatotoxic effect of antireteviral therapy.
AIDSHepatotoxicity after introduction of highly active antiretroviral therapy
200 Citations1998Rafael Rodrı́guez-Rosado, Javier García‐Samaniego +1 more
PubMedHepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy.
194 Citations1995Fortgang Is, Belitsos Pc +2 more
The hepatic steatosis syndrome manifesting as a severe, potentially fatal complication of antiretroviral therapy in HIV disease is rare and both men and women and patients in early and late stages of HIV infection appear to be susceptible.
Annals of Internal MedicineEffects of Lamivudine on Replication of Hepatitis B Virus in HIV-Infected Men
174 Citations1996Yves Benhamou, Christine Katlama +8 more
The efficacy of lamivudine against HBV replication was evaluated in 40 consecutive patients who were infected with both HIV and HBV and who entered this program, and the results are reported after 1 year of follow-up.
AIDSRisks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy
170 Citations2000Pablo Barreiro, Vincent Soriano +4 more
The replacement of PI by NVP seems to be safe both virologically and immunologically, provides a significant improvement in the quality of life and in half of patients ameliorate lipodystrophic body-shape changes at 6 months, although serum lipid abnormalities still remain unmodified.
Annals of Internal MedicineFulminant Hepatic Failure Associated with 2′,3′-Dideoxyinosine (ddI)
161 Citations1991Kwan Kew Lai, David L. Gang +2 more
Results from recently published phase I trials of 2′,3′-dideoxyinosine (didanosine, ddI) show promise in the treatment of patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-...
AIDSHepatomegaly with severe steatosis in HIV-seropositive patients
155 Citations1993Joel Freiman, Karen E. Helfert +2 more
The cases described represent a degree of hepatic abnormalities that has not been reported previously in HIV-seropositive patients, and are probably an underestimate of actual incidence.
AIDSSevere hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations Aquitaine Cohort, France, 1996-1998
146 Citations1999Marianne Savès, Stéphanie Vandentorren +7 more
Hepatic cytolysis is more frequent among patients treated with HAART than with two NRTIs, and co-infections with hepatitis B virus or hepatitis C virus may modify the management of HIV-infected patients treated by HAART.
Expert Opinion on Investigational DrugsDrug Evaluations Anti-infectives: Nevirapine: A review of its development, pharmacological profile and potential for clinical use
130 Citations1996Robert L. Murphy, Joan Montaner
A favourable antiviral effect and CD4+ lymphocyte response has been demonstrated in both adults and children, in patients experienced and naive to antiretroviral therapy as well as in those with baseline resistance to zidovudine.
The LancetSevere hepatitis in three AIDS patients treated with indinavir
115 Citations1997Norbert Bräu, Howard L. Leaf +2 more
Antimicrobial Agents and ChemotherapyHepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus-Infected Patients
115 Citations2000Marianne Savès, François Raffi +9 more
In a cohort of 1,047 human immunodeficiency virus type 1-infected patients started on protease inhibitors, the incidence of severe hepatic cytolysis was 5% patient-years after a mean follow-up of 5 months.
AIDSEfficacy and safety of combination therapy with interferon-α2b and ribavirin for chronic hepatitis C in HIV-infected patients
98 Citations2000Alain Landau, Dominique Batisse +8 more
AIDS Research and Human RetrovirusesChange in Transaminases in Hepatitis C Virus- and HIV-Coinfected Patients after Highly Active Antiretroviral Therapy: Differences between Complete and Partial Virologic Responders?
41 Citations2000G. Gavazzi, O Bouchard +6 more
It is suggested that the restoration of CD8+ T cell cytotoxicity could lead to an enhancement of hepatitis C-related disease in HCV/HIV-coinfected patients receiving HAART.
AIDSRibavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment
39 Citations2000Giulia Morsica, Anna De Bona +4 more
Expert Opinion on Investigational DrugsEfavirenz: shifting the HAART paradigm in adult HIV-1 infection
30 Citations1999Graeme Moyle
An open-label comparison versus indinavir plus two nucleoside analogues in predominantly treatment-naïve patients, demonstrated that the efavirenz-based triple therapy provides at least similar antiviral effects, and possibly stronger effects, over 48 weeks.
JAIDS Journal of Acquired Immune Deficiency SyndromesInterferon Plus Ribavirin in HIV-Infected Patients With Chronic Hepatitis C
28 Citations1999Mayte Pérez‐Olmeda, Juan González +4 more
Medicina ClínicaEficacia del tratamiento antirretroviral en pacientes con infección por el virus de la inmunodeficiencia humana. Estudio de 807 pacientes
15 Citations2000María Socas, Juan Luis Gómez Sirvent +8 more
El uso of the terapia combinada de alta eficacia produce un marcado beneficio in the supervivencia of los pacientes with infeccion por el VIH independientemente del grado of in-munodepresion.
JAIDS Journal of Acquired Immune Deficiency SyndromesInterferon Plus Ribavirin in HIV-Infected Patients With Chronic Hepatitis C
9 Citations1999Mayte Pérez‐Olmeda, Juan González +4 more